期刊文献+

1型糖尿病病人骨密度的变化及其影响因素 被引量:1

BONE DENSITY AND ITS INFLUENCING FACTORS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
下载PDF
导出
摘要 目的观察1型糖尿病病人骨密度(BMD)的变化及其影响因素。方法采用双能X线骨密度测量仪,测定108例1型糖尿病病人及106例非糖尿病人腰1(L1)~L4及左侧髋部(股骨颈、大转子、ward三角、股骨干及左髂骨总体)BMD,同时测定受试者年龄、身高、体质量、腰围、臀围、病程、糖化血红蛋白(HbA1c)等指标。结果两组各部位BMD比较,差异有显著性(t=-7.105^-3.022,P<0.01)。1型糖尿病病人L1~L4总体BMD和左髂骨总体BMD与年龄、HbA1c呈负相关(β=-0.410^-0.148,P<0.05),与BMI正相关(β=0.673、0.054,P<0.05);左髂骨总体BMD与性别有关(β=-0.208,P<0.05)。结论 1型糖尿病病人BMD低于对照人群,1型糖尿病病人的性别、年龄、BMI、HbA1c水平与BMD关系密切。 Objective To investigate the bone mineral density(BMD)and its influencing factors in type 1diabetic(T1DM). Methods BMD at the lumbar spine(L1-L4)and femur(neck,ward triangle,trochiter,shaft of femur,left ilium)were measured in 108patients with T1DM and 106controls using dual-energy X-ray absorptiometry(DXA).The age,height,body weight,waistline,hip circumference,course of disease,and glycosylated hemoglobin(HbA1c)were detected in all the subjects. Results The differences of BMD in each part detected between the two groups were significant(t=-7.105--3.022,P〈0.01).In type 1diabetic patients,the BMD in L1-4total and left hip total were correlated with HbA1clevel and age(β=-0.410--0.148,P〈0.05),and BMI(β=0.673,0.054;P〈0.05).The BMD in left hip total was associated with gender(β=-0.208,P〈0.05). Conclusion BMD in type 1diabetic patients was significantly lower than control subjects;which is closely related with the patient's,sex,age,BMI and HbA1c.
出处 《青岛大学医学院学报》 CAS 2014年第4期342-344,共3页 Acta Academiae Medicinae Qingdao Universitatis
关键词 糖尿病 1型 骨密度 因素分析 统计学 diabetes mellitus type 1 bone density factor analysis statistical
  • 相关文献

参考文献3

二级参考文献30

  • 1田景琰,张宏利,顾燕云,李风英,徐佳,王晓,骆天红,李果,罗敏.胰淀素对大鼠胰岛素和胰高血糖素分泌的影响[J].上海交通大学学报(医学版),2006,26(8):856-859. 被引量:4
  • 2Brown SA, Sharpless JL Osteoporosis: An underappreciated complica- tion of diabetes [J]. Clin Diabetes, 2004, 22 (1) : 10 -20.
  • 3Neumann T, Samann A, Lodes S, et al. Glycaemic control is positivelyassociated with prevalent fractures but not with bone mineral density in patients with type 1 diabetes [J]. Diabet Med, 2011, 28 (7) : 872 - 875.
  • 4Mastrandrea LD, Wactawski -Wende J, Donabue RP, et al. Young women with type 1 diabetes have lower bone mineral density that persists over time [J]. Diabetes Care, 2008, 31 (9) : 1729 -1735.
  • 5Hamilton E J, Rakic V, Davis WA, et al. Prevalence and predictors of osteopenia and osteoporosis in adults with type 1 diabetes [ J ]. Diabet Med, 2009, 26 (1): 45-52.
  • 6Strotmeyer ES, Cauley JA, Orchard TJ, et al. Middle - aged premeno- pausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women [ J ]. Diabetes Care, 2006, 29 (2): 306-311.
  • 7Ingberg CM, Palm6r M, Aman J, et al. Body composition and bone mineral density in long - standing type 1 diabetes[ J]. J Intern Med, 2004, 255 (3) : 392 -398.
  • 8Heilman K, Zilmer M, Zilmer K, et al. Lower bone mineral density in children with type 1 diabetes is associated with poor glycemie control and higher serum ICAM - 1 and urinary isoprostane levels [J]. J Bone Min- er Metab, 2009, 27 (5): 598-604.
  • 9Hadjidakis DJ, Raptis AE, Sfakianakis M, et al. Bone mineral density of both genders in type 1 diabetes according to bone composition [J]- J Diabetes Complications, 2006, 20 (5): 302-307.
  • 10Rakel A, Sheehy O, Rabme E, et al. Osteoporosis among patients with type 1 and type 2 diabetes [ J ]. Diabetes Metab, 2008, 34 (3) : 193 -205.

共引文献130

同被引文献27

  • 1Janghorbani M, Hu FB, Wiliett WC, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care. 2007;30(7):1730-1735.
  • 2Neumann T, S:imann A, Lodes S, et al. Glycaemic control is positively associated with prevalent fractures but not with bone mineral density in patients with Type 1 diabetes. Diabet Med. 2011 ;28(7):872-875.
  • 3Cosman F. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates Endocr Pract. 2009; 15(5):483-493.
  • 4Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am. 2012;41 (3): 487-506.
  • 5Huang S, Lin H, Zhu X, et al. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis. Endokrynol PoI. 2014;65(2): 96-104.
  • 6Terpos E, Dimopoulos MA, Berenson J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit Rev Oncol Hematol. 2011 ;77 Suppl 1 :$13-23.
  • 7Kamiya N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr Mol Pharmacol. 2012; 5(2):153-163.
  • 8Liu EY, Wactawski-Wende J, Donahue RP, et al. Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care. 2003;26(8):2365-2369.
  • 9Heap J, Murray MA, Miller SC, et al. Alterations in bone characteristics associated with glycemic control in adolescents with type 1 diabetes mellitus. J Pediatr. 2004; 144(1 ): 56-62.
  • 10Ebeling PR, Burr DB. Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible? J Bone Miner Res. 2008;23(1):2-5.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部